DFX Intelligence
The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Credit Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.
Borrower
A••••••• I••
Drug Discovery & Developmentgroup grade Bon a schedule nowsponsor unattributed
Also written as: Inc. and
What matters now
- 99¢ → 102¢consensus mark
Consensus mark 102¢ on cost, up from 99¢ a year ago, 100¢ last quarter.
Q2 2026 · The lenders' own valuations moved back up.
Derived1 of 1 lender' own marks, weighted by principal
Mark path, consensus per quarter end
99¢ · 101¢ · 100¢ · 100¢ · 102¢Q2 2025 to Q2 2026
Principal held
at least $7.0M
sum of BDC pieces, a lower bound
Fair value
$7.3M
102c on cost, debt pieces
Unfunded
$0
commitments not yet drawn
BDC lenders
1
1 on the latest quarter
Facilities
1
1 equity pieces beside them
Next maturity
Dec 1, 2028
no dated debt inside 24 months
On the tape since
Dec 31, 2024
latest Jun 30, 2026
Events
1
dated, non-routine
Lender marks
each lender's own fair value over cost at Jun 30, 2026, folded to one row per lender
| Lender | Exposure | Current mark | QoQ change |
|---|---|---|---|
| H••••••• C••••••• I••• | $7M | 102¢ | +2 pts |
Every BDC piece · 2 positions across 1 lenderlargest principal first, with instrument and rate
| BDC | Instrument | Principal | Fair value | Rate |
|---|---|---|---|---|
| H••••••• C••••••• I••• | term loan first lien S••••• S••••••, D••••••• 2028, P•••• + 1.05%, F•••• rate 8.05%, 4.75% E••• Fee | $7.0M | $7.3M 102c | S+105 bp |
| H••••••• C••••••• I••• | unstated lien unstated | Not disclosed | Not disclosed |
Capital structure as the BDCs see it
latest quarter end Jun 30, 2026
| Facility | Held | On cost | Pricing | Maturity | BDCs |
|---|---|---|---|---|---|
| first lien term loan first lien | at least $7.0M | 102c | S+105 bp | Dec 1, 2028 | 1 |
Equity pieces beside the debt: other (Not disclosed fair value, 1 BDC)
Through time
the borrower's pieces summed across BDCs, every quarter end
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Jun 30, 2026 | 1 | $7.0M | $7.3M | 102c | 0 |
| Mar 31, 2026 | 1 | $7.0M | $7.1M | 100c | 0 |
| Dec 31, 2025 | 1 | $14.0M | $14.1M | 100c | 0 |
| Sep 30, 2025 | 1 | $7.0M | $7.1M | 101c | 0 |
All 7 quartersShow fewer
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Jun 30, 2025 | 1 | $7.0M | $6.9M | 99c | 0 |
| Mar 31, 2025 | 1 | $7.0M | $7.0M | 100c | 0 |
| Dec 31, 2024 | 1 | $7.0M | $6.9M | 100c | 0 |
What changed
- New borrower on a BDC scheduleDec 31, 2024
Sponsor
No sponsor attribution: no portfolio page, deal announcement or Form D signer consensus names an owner for this borrower group.
Identity
- Group key
- ALECTORderivedthe codename stem after legal suffixes and deal words
- Spellings
- 1 across 1 BDCderived
- Industry
- Drug Discovery & Developmentreportedas one filer wrote it